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Abstract
Methods are presented for the use of the coral 8R-lipoxygenase from the Caribbean sea
whip coral Plexaura homomalla as a model enzyme for structural studies of animal
lipoxygenases. The 8R-lipoxygenase is remarkably stable and can be stored at 4°C for
3 months with virtually no loss of activity. In addition, an engineered “pseudo wild-type”
enzyme is soluble in the absence of detergents, which helps facilitate the preparation of
enzyme:substrate complexes.

1. INTRODUCTION
The discovery of prostaglandins in Plexaura homomalla in 1969
(Weinheimer & Spraggins, 1969) eventually led to the identification of
cyclooxygenase (COX) and lipoxygenase (LOX) biosynthetic pathways
in corals. While the functions of the oxylipins these enzymes generate
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remain undefined, P. homomalla 8R-LOX has proven to be a remarkably stable homologue of human 5-LOX, with which it shares 40% sequence
identity. This is the same level of sequence identity observed between
5-LOX and its closest intraspecies orthologue 15-LOX-2. Human
5-LOX is the only clinically validated drug target of the LOX family, but
the enzyme’s short half-life has made biochemical characterization difficult
(Carter et al., 1991; Percival, Denis, Riendeau, & Gresser, 1992; Wenzel
et al., 2007). The extraordinary stability of the coral enzyme makes it a
highly tractable system for structural studies, as protein instability is a
frequent roadblock to structural studies (Deller, Kong, & Rupp, 2016),
and 8R-LOX structures have revealed key mechanistic details of the
LOX oxygenation reaction. Although 8R-LOX was originally identified
as the C-terminal region of a naturally occurring fusion protein (Gilbert
et al., 2008; Koljak, Boutaud, Shieh, Samel, & Brash, 1997), we will focus
on the isolated LOX domain in this report (Boutaud & Brash, 1999; Brash,
Boeglin, Chang, & Shieh, 1996; Oldham, Brash, & Newcomer, 2005).
LOXs are nonheme iron enzymes that catalyze the regio- and stereospecific dioxygenation of polyunsaturated fatty acids at a cis, cis-1,4-pentadiene
(Boutaud & Brash, 1999), often to generate a potent lipid-signaling mediator. The enzymes have been found in animals, plants, bacteria, and fungi,
with certain species harboring a catalytic manganese instead of iron
(Andreou & Feussner, 2009; Boutaud & Brash, 1999; Hamberg, Su, &
Oliw, 1998; Kuhn & Thiele, 1999). The common substrate for animal
LOXs is arachidonic acid (AA), an ω6 20-carbon fatty acid with four
double bonds. There are 3 pentadienes in AA with the potential for
12 unique oxidation products that can be produced by a single LOX reaction
(Fig. 1A). The overall tertiary structure of plant (Boyington, Gaffney, &
Amzel, 1993) and animal (Gillmor, Villasenor, Fletterick, Sigal, &
Browner, 1997) LOXs shares a common fold. These LOXs contain an
N-terminal β-barrel domain of 15 kDa, which may harbor Ca2+-binding
residues and membrane-insertion loops that target the enzyme to the membrane periphery (Fig. 1B). The much larger (4 ) C-terminal domain of
LOX positions the catalytic iron at the base of a U-shaped cavity (Fig. 1C).
The Fe2+ is chelated by invariant histidines and the main chain carboxy
terminus (Minor et al., 1996; Newcomer & Brash, 2015; SkrzypczakJankun, Bross, Carroll, Dunham, & Funk, 2001; Xu, Mueser, Marnett, &
Funk, 2012).
Our initial work with the 8R-LOX domain of the P. homomalla fusion
protein led to a 3.2 Å resolution structure (Oldham et al., 2005).

Expression of an 8R-Lipoxygenase

35

Fig. 1 Lipoxygenase reaction and structure. (A) Arachidonic acid has three pentadienes
with hydrogens on carbon 7, 10, and 13 (smaller font and colored blue, red, and green,
respectively, or different shades of gray) that are possible sites of attack by LOX enzymes.
Notice in the online version of the figure that carbons are colored with respect to the
hydrogen that needs to be abstracted for oxygenation to occur at that carbon. For
example, hydrogen abstraction on carbon 10 (red) will result in oxygen addition at either
carbon 8 or 12 (both red), depending on the particular enzyme. (B) 8R-LOX WT (PDB
code 2fnq) and 8R-LOX psWT (PDB code 3fg1) are superimposed for comparison.
Membrane-insertion loops and Ca2+-binding residues have been deleted from the latter. Detailed view of N-terminal domain (framed box in panel C) with 8R-LOX WT shown
in blue or dark gray and 8R-LOX psWT shown in white. Spheres are bound Ca2+ as seen in
the 8R-LOX WT structure. Residues (blue/dark gray) that are highlighted are either Ca2+binding residues 43–45 (His-Asn-Asp) or membrane-insertion residues 41–42 (Trp-Phe).
Residues shown in white are membrane-binding residues Tyr 77 and Trp 78. (C) Cartoon
rendering of 8R-LOX WT shown in blue or dark gray and 8R-LOX psWT shown in white.
The catalytic domain is mainly α-helical and harbors the catalytic iron (orange/gray
sphere).

Examination of crystal packing led us to suggest that a membrane-insertion
loop interfered with packing of the protein molecules in the crystal lattice.
We reasoned that removal of an extended hydrophobic loop, which penetrated a neighboring molecule, might facilitate a tightly packed lattice that
could provide us with higher resolution X-ray data (Fig. 1B). Deletion of
a membrane-insertion loop (8R-LOX Δ41-45GS) from the PLAT
(polycystin-1, LOX, Alpha-Toxin) domain of 8R-LOX by mutagenesis
yielded an enzyme with increased solubility (Fig. 2). The construct was
given the moniker “pseudo-wild type (psWT)” because it retains the
in vitro enzymatic activity of its progenitor, despite the lack of both a
membrane-binding loop and Ca2+-binding amino acids necessary for membrane targeting (Neau, Gilbert, Bartlett, Dassey, & Newcomer, 2007). As
hoped, the mutant provided crystals that diffract to 1.9 Å resolution and
amenable to the manipulation required for an anaerobic enzyme:substrate
complex (Neau et al., 2014, 2009). The latter structure revealed the AA substrate positioned in the U-shaped active site in a pose consistent with the
regio- and stereospecificity of 8R-LOX, and hence provided a robust model
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Fig. 2 Sequence alignment of four human lipoxygenases with the coral 8R-LOX and
its deletion mutant psWT. The PDB codes are included if a sequence from a solved
protein structure was used. The box frames the area of the protein sequence where
Ca2+-binding residues and membrane-insertion residues were mutated. The * represents amino acids that bind Ca2+ in the N-terminal domain. The • represents amino acids
known to peripherally bind the membrane. The amino acid sequence WFHND of 8R-LOX
was mutated to GS to generate 8R-LOX psWT. The amino acid sequence PFYND of 5-LOX
was mutated to GS to generate a soluble 5-LOX known as Stable-5-LOX.

for understanding LOX product specificity in this superfamily
(Newcomer & Brash, 2015). The protein engineering strategy of removing
a LOX membrane-insertion loop has been applied to additional LOX
(Mittal et al., 2017) and yielded a protein amenable to crystallization
(Gilbert et al., 2011).

2. PREPARATION OF HIGHLY PURIFIED 8R-LOX
Having homogenous and monodisperse protein is generally an important prerequisite for obtaining diffraction-quality crystals suitable for highresolution structure determination. For the case of 8R-LOX, an ample
amount of protein can be expressed in Escherichia coli with low temperature
incubation of the cultures in the autoinduction media first described by
Studier (2005).

2.1 Transformation of 8R-LOX psWT Into Overexpression Host
The pET-3a plasmid harboring 8R-LOX psWT is transformed into BL21
(DE3) cells using the heat-shock protocol.
2.1.1 Equipment
• 42°C water bath for heat-shock transformation
• 37°C benchtop shaking incubator
• 37°C incubator for overnight incubation of agar plates
2.1.2 Buffers and Reagents
• E. coli BL21 (DE3) cells (Invitrogen)
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SOC media—2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM
KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose (Invitrogen)
Luria–Bertani (LB) broth with 10 g peptone, 5 g yeast extract, and 5 g
NaCl (Research Products International)
Carbenicillin (100 μg/mL final concentration) (P212121)

2.1.3 Procedure
1. 10 μL of E. coli BL21 (DE3) cells are thawed on ice. 50 ng of plasmid
DNA is added to thawed cells and tube is flicked 4–5 times to mix
the cells.
2. The mixture is incubated on ice for 5 min.
3. The mixture is placed in a 42°C bath for 45 s and returned back to ice for
2 min.
4. 200 μL of prewarmed SOC media is added, and the mixture is transferred
to a 14-mL round bottom falcon tube.
5. The tube is placed at 37°C for 45 min in incubator and is vigorously
rotated.
6. The mixture is plated on LB plate with carbenicillin and incubated overnight at 37°C.
2.1.4 Notes
1. Transformation efficiency is reduced with multiple freeze/thaw cycles of
the competent cells.
2. We routinely only use 10 μL of competent cells, which is one-fifth of the
volume aliquoted by the supplier. The other portion of competent cells
is transferred to sterile 1.5-mL microcentrifuge tubes in aliquots of 10 μL
and placed in 80°C.
3. We do not store glycerol stocks of transformed bacteria as they do not
necessarily provide the generous yields that freshly transformed bacteria
do. We invariably start each preparation with freshly transformed cells.

2.2 Expression of 8R-LOX
2.2.1 Equipment
• Large, high-capacity floor model orbital shaker with refrigeration capabilities (Infors HT, Multitron model)
• Standard SDS-PAGE equipment, 10% SDS-PAGE gels
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2.2.2 Buffers and Reagents
• Autoinducing media ZYM-5052 is a media for growing high-density
shake-flask cultures that upon saturation will autoinduce protein expression (Studier, 2005). ZYM-5052 contains:
i. 1% N-Z-amine AS, 0.5% yeast extract, abbreviated ZY and is
autoclaved separately
ii. 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM
Na2SO4, abbreviated 50  M and is autoclaved separately at 50 
concentration
iii. 2 mM MgSO4, made at a concentration of 1.0 M and autoclaved
separately
iv. 0.5% glycerol, 0.05% glucose, 0.2% α-lactose, abbreviated as
50  5052, made at 50  concentration, and sterile filtered
• Optional: IPTG (isopropyl β-D-1-thiogalactopyranoside) used at
500 μM final concentration (Research Products International)
2.2.3 Procedure
1. A single colony from the plate is used to inoculate (2) 25 mL LB in
125-mL Erlenmeyer flask with carbenicillin for selection.
2. Shake flasks are grown overnight in the incubator at 220 rpm, 37°C.
3. (8) 480 mL of ZY media is prepared in a nonbaffled 2-L Erlenmeyer
flask the day before inoculation along with stocks of 1.0 M MgSO4,
50  M, and 50  5052. (Pro hint: LOX expression is very sensitive to
aeration of the media. Flask size, baffles vs nonbaffles, and temperature
along with rpm should be followed carefully according to protocol).
4. 2.0 mL of the overnight culture is added to each flask along with 10 mL
of 50  M and 50  5052, and 1 mL of 1.0 M MgSO4.
5. Cultures are grown at 37°C, 220 rpm for 4 h.
6. The temperature is dropped to 20°C and grown overnight. On the next
morning, the optical density of the cultures is monitored by absorbance
at 600 nm. It is key to make sure that the bacterial growth is past log phase
and has entered the stationary phase otherwise autoinduction does not
occur. Upon saturation of culture, lactose is transported inside the bacterial cell, and β-galactosidase converts the lactose to allolactose. Allolactose induces expression of the protein of interest by binding the
lac repressor, which now allows T7 RNA polymerase to bind the lac
promoter and produce the mRNA transcripts for 8R-LOX psWT.
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7. The cells usually reach saturation that afternoon and are harvested and
centrifuged at 5000  g for 10 min. Pellets are frozen at 80°C until
further use.
2.2.4 Notes
1. IPTG may be added 4 h before harvest if uncertain about having reached
a stationary phase and therefore having undergone autoinduction overexpression of 8R-LOX psWT.
2. Protein expression can be checked by taking a 1-mL sample of growth at
harvest. The sample is spun down at 13,000 rpm in microcentrifuge.
A volume of 300 μL of Bugbuster® is added and then incubated at
4°C while nutating for 1 h. Soluble and insoluble material is separated
by centrifugation at 13,000 rpm and samples are run on SDS-PAGE
gel. 8R-LOX psWT migrates 75 kDa and should appear in the soluble
fraction.

2.3 Purification of 8R-LOX
This three-step purification can be completed in 2 days and yields highly
purified enzyme (10 mg enzyme per 1 L of expression media) that is amenable to high-resolution structural studies (Fig. 3).
2.3.1 Equipment
• Branson Sonifier 250 (VWR Scientific)
• FRENCH® Pressure cell press (SLM Instruments, Inc. of Milton Roy
company)
• Nalgene syringe filter, 25 mm cellulose acetate membrane, 0.8 μm
(ThermoFisher Scientific)
• DynaLoop 90, store in 20% ethanol (Bio-Rad)
• AKTA FPLC (GE Healthcare Life Sciences)
• HisTrap HP 5 mL column (GE Healthcare Life Sciences)
• Dialysis tubing with average flat width 25 mm, 14 kDa cutoff (Sigma).
Tubing is washed under running water for 2 min before use. Residual
glycerin and sulfur compounds from dialysis tubing do not appear to
affect purification of the 8R-LOX psWT protein.
• Mono-Q (10/100 GL) anion exchange (GE Healthcare Life Sciences)
• Spin-X® UF 20 mL Concentrator 30,000 molecular weight cutoff
(Corning)
• Nanodrop™ 2000 Spectrophotometer (ThermoFisher Scientific)
Molecular weight of protein is 79,000 Da and theoretical molecular

Fig. 3 Purification of 8R-LOX psWT by immobilized metal-affinity chromatography. The y-axis is the milli-absorbance at 280 nm, and x-axis the
elution volume. Cell lysate (80 mL) was loaded onto a HisTrap HP 5 mL column followed by 100 mL of wash with equilibration buffer. Bound
8R-LOX psWT is eluted by a gradient of increasing concentration of buffer B (200 mM imidazole). Fractions 4 through 7 were collected and
used for further purification.
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extinction coefficient that is used is 137,000 for measuring protein
concentration.
Hiload 16/600 Superdex 200 10/300 PG (GE Healthcare Life Sciences)
Vial Clamp™ curved (Hampton Research)
Long-handled tweezers with serrated tip and furrowed handle (Grainger)
Low form shallow dewar with hemispherical bottom (Pope Scientific
Inc.) (see Fig. 4)

2.3.2 Buffers and Reagents
• Bugbuster®, bacterial chemical lysis reagent with detergent (Novagen)
• DNase I from bovine pancreas (Sigma)
• Leupeptin (5 μg/mL final concentration), pepstatin (10 μM final concentration, Sigma), and PMSF (phenylmethylsulfonyl fluoride, Sigma)
• Immobilized affinity chromatography (IMAC) buffer A: 20 mM Tris pH
8.0/500 mM NaCl/20 mM imidazole pH 8.0
• IMAC buffer B: 20 mM Tris pH 8.0/500 mM NaCl/200 mM imidazole
pH 8.0
• Anion-exchange buffer A: 20 mM Tris pH 8.0
• Anion-exchange buffer B: 20 mM Tris pH 8.0 and 500 mM NaCl
• Size exclusion chromatography (SEC) buffer: 20 mM Tris pH 8.0 and
150 mM NaCl

Fig. 4 Cryocooling of purified 8R-LOX psWT. The low form shallow dewar with hemispherical bottom is shown without liquid N2. The curved vial clamp™ and tweezers
have been placed on top of the dewar. Inset in bottom left corner shows protein that
has been cryocooled in the liquid N2, collected by long-handled tweezers, and placed
into cryocooled microcentrifuge tube that is held by the curved vial clamp™. Protein
beads are not clearly discerned due to fogging of cryocooled tube.
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2.3.3 Procedure
1. Cell pellets containing expressed 8R-LOX psWT are weighed out in a
250-mL plastic beaker. Typical growth from 4 L of media results in
45 g of cell pellet.
2. Bugbuster® is added at customized ratio of 2.0 mL of Bugbuster® per
1.0 g of cell pellet. Manufacturer recommends 5.0 mL of Bugbuster®
per 1.0 g of cell pellet.
3. DNase I (100 Kunitz) is added along with PMSF (2 mg of crystalline
material), pepstatin, and leupeptin. The solution is homogenized on a
stir plate for 10 min in an ice-bath.
4. Mixture can either be:
a. Sonicated (3) for 2 min, 50% duty, and output control of 8 out of
10 on Branson Sonifier 250. Between cycles of sonication, mixture
is cooled on ice for 5 min.
b. French pressed with pressure >16,000 psi on FRENCH® Pressure
cell press. The French pressure system that is utilized allows
40 mL of mixture to be pressed per pass. Typical output time is
5 min per 40 mL. Once the mixture is passed through the press,
the solution is immediately placed in an ice-bath. Note: French
press lysis yields larger amounts of protein due to better lysis of cells
and less loss due to denaturation.
5. Mixture is centrifuged at 40,000  g for 45 min at 4°C to clarify lysate
and to pellet insoluble portion.
6. Supernatant is filtered by 0.8-μm syringe filter and loaded onto superloop (DynaLoop 90).
7. HisTrap HP 5 mL column is equilibrated with 20 mM Tris pH
8.0/500 mM NaCl/20 mM imidazole pH 8.0 on FPLC until UV and
conductivity are stable baselines (usually 5 column volumes, make sure
to pH both Tris and imidazole).
8. Supernatant from superloop is loaded onto column at 2 mL/min.
9. Column with bound protein is washed with 100 mL of equilibration
buffer.
10. Protein is eluted using a linear gradient of 100% B over 20 column volumes with 5 mL fractions. Buffer B is similar to equilibration buffer but
with 200 mM imidazole pH 8.0.
11. Fractions that contain protein as monitored by absorbance at 280 nm
are collected from the middle of the Gaussian peak. Shoulder fractions
lower than one-third of the peak height are discarded.
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12. Peak fractions are pooled and placed in dialysis tubing and dialyzed
overnight in 2 L of 20 mM Tris pH 8.0 in cold room.
13. The next day, the Mono-Q anion-exchange column is equilibrated
with 20 mM Tris pH 8.0 on the FPLC until the UV and conductivity
signals have stable baselines.
14. Protein that was dialyzed overnight is syringe filtered and loaded onto
cleaned superloop.
15. Protein is injected onto Mono-Q from the superloop at 2 mL/min and
the column is washed with 40 mL (5 column volumes) of equilibration
buffer.
16. Protein is eluted with linear gradient from 0% to 100% B over 10 column volumes with 5 mL fractions. Buffer B contains 20 mM Tris pH
8.0 and 500 mM NaCl.
17. Once again fractions that contain protein as indicated by A280 are collected from the middle of the Gaussian peak using a similar shoulder
cutoff.
18. Peak fractions are pooled and concentrated in Spin-X® UF 20 mL
Concentrator with 30,000 molecular weight cutoff. Protein is concentrated to 2 mL and 20 mg/mL as measured on a Nanodrop™.
19. Protein is loaded onto 2.0 mL loop and injected onto Hiload 16/600
Superdex 200 10/300 PG equilibrated in 20 mM Tris pH
8.0/150 mM NaCl.
20. Monomeric protein elutes 80 mL, and 1 mL peak fractions are pooled
and concentrated in Spin-X® UF 20 mL Concentrator with 30,000
molecular weight cutoff until protein reaches 10 mg/mL.
21. Protein purity is accessed by a 10% SDS-PAGE gel run at 150 V for
75 min.
22. Purified protein is slowly dripped from a transfer pipette into liquid N2
in a shallow dewar. The protein beads are typically 25 μL. The protein beads are collected into a cryocooled microcentrifuge tube held
with vial clamps, and subsequently placed in 80°C freezer.
2.3.4 Notes
1. For cell lysis, our lab usually both sonicates and then uses the French
press. Sonication is used to make the sample more homogeneous, which
makes using the French press easier. Just make sure not to overheat the
lysate solution.
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2. The expression yield of 8R-LOX psWT is robust so do not be afraid to
cutoff shoulders of protein peaks. We see more reproducible crystal
growth conditions for 8R-LOX psWT when we keep only the peaks
from the chromatography runs.
3. When freezing the purified 8R-LOX psWT into liquid N2, drip the protein just a few drops at a time. This allows for independent freezing of the
protein drops instead of protein drops coming together to make larger
aliquots.
4. After placing protein drops into cryocooled microcentrifuge tube, make
sure that there is no residual liquid N2 in the tube before closing. Failure
to boil all liquid N2 from the microcentrifuge tubes can result in the lid
blowing off along with your protein beads spilling onto the floor. (Hint:
I hold microcentrifuge tube in fingers for about 30 s before closing lid.
This is about the time it takes me to walk to the 80°C freezer.)

3. STRUCTURAL STUDIES OF 8R-LOX
The molecular weight of 8R-LOX at 79 kDa makes crystallography
the ideal tool for structural studies, with the enzyme being too large for
NMR and too small for Cryo-EM. Crystallization of 8R-LOX or 8RLOX psWT has only been successful in conditions that include Ca2+, a
cofactor for the membrane-insertion loops on the N-terminal domain
(Neau et al., 2014, 2009, 2007; Oldham et al., 2005). To get an enzyme:substrate complex trapped, the crystals must be grown in an anaerobic environment. LOXs insert molecular O2 on the fatty acid, so growing 8R-LOX
psWT crystals in an anaerobic environment is the first step to obtaining
an enzyme:substrate complex. The second step is soaking these anaerobic
crystals with AA in a glove box and cryocooling in the anaerobic environment before X-ray data collection.

3.1 Anaerobic Crystallization of 8R-LOX
3.1.1 Equipment
• Vinyl anaerobic chamber (Coy Laboratory Products)
• Sitting drop crystallization plate, such as the Cryschem Plate (Hampton
Research)
• Crystal Clear Sealing Tape or Crystal Clear Sealing Film (Hampton
Research)
• Mounted cryoloop for crystal harvesting (Hampton Research)
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3.1.2 Buffers and Reagents
• 10 mg/mL 8R-LOX psWT in 150 mM NaCl, 20 mM Tris, pH 8.0
• 25% (w/v) PEG-8000 (FLUKA brand)
• 50% (v/v) Glycerol
• 2 M CaCl2
• 1 M Imidazole acetate, pH 8.0
3.1.3 Procedure (Carried Out Inside the Anaerobic Chamber)
1. Crystallization reagents and buffers should be degassed before bringing
them into the anaerobic chamber. Solutions should be transferred to
the anaerobic chamber immediately after degassing to keep them from
absorbing oxygen. Two alternative methods of degassing are presented
below.
a. Solutions can be degassed by placing them into a round bottom flask
and pulling a slight vacuum on the flask while stirring or sonicating
the solution and then refilling the flask with an inert gas, such as
nitrogen or argon. This should be done 3–5 times, pulling the vacuum for about 5 min each time before refilling with the inert gas.
b. Solutions can also be degassed by sealing them in a flask and bubbling
an inert gas through the solution while sonicating for 30 min to an
hour.
2. In the well of the crystallization tray, mix the following amounts of the
crystallization reagents:
• 200–320 μL 25% PEG-8000 (200 μL in first row, increase by 40 μL
each row after)
• 100 μL 50% Glycerol
• 100 μL 2 M CaCl2
• 100 μL Imidazole acetate, pH 8.0
• Bring volume of well to 1000 μL by addition of deionized water
This creates well solutions of 5%–8% PEG-8000, 5% glycerol,
0.2 M CaCl2, and 0.1 M imidazole acetate, pH 8.0
3. Place 4 μL of 10 mg/mL 8R-LOX psWT on all of the pedestals of the
crystallization plates, then immediately pipette 4 μL of well solution into
the protein drop.
4. Seal the top of the crystallization plate using either clear sealing tape or
clear sealing film.
5. Incubate the trays at room temperature. Crystals should appear in
1–2 days. Crystals typically grow with a rod-shaped, rhombic crystal
habit. Occasionally the crystals will appear more blocky than rod-like.

46

Nathaniel C. Gilbert et al.

6. Cryosolution for cooling of crystals is prepared by mixing 500 μL of 50%
glycerol, 400 μL of 25% PEG-8000, 10 μL of 2 M CaCl2, and 100 μL of
imidazole acetate, pH 8.0 (final solution is approximately 25% glycerol,
10% PEG-8000, 0.02 M CaCl2, 0.1 M imidazole acetate, pH 8.0).
7. Crystals are prepped for data collection by using a sharp blade to cut away
the sealing film over a crystallization drop then looping a crystal from the
crystallization drop with a mounted cryoloop and transferring it into a
small drop (5–10 μL) of cryosolution. The crystal can then be immediately looped again and plunged into liquid N2 to vitrify the crystal.
3.1.4 Notes
1. Aerobic crystals of 8R-LOX psWT can be grown using the same procedure as above, simply set up trays outside of the anaerobic chamber.
In this case, solutions do not need to be degassed and crystals can be
grown in hanging drop crystals plates as an alternative to the sitting drop
plates.
2. It is not feasible to degas the protein solution. Simply transfer the amount
of protein needed for crystallization into the anaerobic chamber in an
open Eppendorf tube.
3. Liquid N2 can be brought into the anaerobic chamber in a bowl dewar.
When taking the liquid N2 through the antechamber it has a tendency to
boil violently during the first purge cycle of the antechamber. If this boiling causes too much liquid N2 to spill in the antechamber, it will volatilize quickly enough to overpressure the antechamber, potentially
contaminating the anaerobic chamber. To minimize this risk, pull vacuum slowly during the first purge cycle if the vacuum is manually controlled. Liquid N2 tends to make the oxygen level rise in the anaerobic
chamber as it boils off. As long as oxygen stays below 50 ppm, the system should still be considered anaerobic.

3.2 Preparation of 8R-LOX:AA Binary Complexes
3.2.1 Equipment
• Small plastic petri dishes (1.5–2 in. in diameter)
• Syringe of vacuum grease. Hint: use a normal plastic syringe (maybe 5 or
10 cc) filled with vacuum grease and place a P200 pipette on the tip of the
syringe for fine control as an applicator.
3.2.2 Materials
• Anaerobic 8R-LOX psWT crystals
• Arachidonic acid
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Anaerobic 8R-LOX psWT cryosolution: 25% glycerol, 10% PEG-8000,
0.02 M CaCl2, 0.1 M imidazole acetate, pH 8.0
DMSO

3.2.3 Procedure (Carried Out Inside the Anaerobic Chamber)
1. Dilute AA to 100 mg/mL using DMSO.
2. Dilute the AA further to 1 mg/mL by adding 1 μL of the 100 mg/mL AA
solution to 99 μL of the 8R-LOX psWT cryosolution.
3. Apply a bead of vacuum grease to the inside edge of the lid of the
petri dish.
4. Place 1.0 mL of 8R-LOX psWT cryosolution into the bottom of the
petri dish.
5. Put a 5.0 μL drop of the 1 mg/mL AA solution on the inside surface of
the lid of the petri dish.
6. Using a mounted cryoloop, transfer an anaerobic 8R-LOX psWT crystal
into the drop of AA solution.
7. Invert the lid and seal it onto the bottom of the petri dish, so that the drop
containing the crystal is suspended over the 1.0 mL of cryosolution. The
1.0 mL of cryosolution prevents the soaking drop from drying out.
8. Allow the crystal to soak overnight (16 h).
9. Loop the crystal from the soaking drop and immediately plunge into liquid nitrogen.
3.2.4 Notes
1. Cocrystallization of 8R-LOX psWT with AA has not been successful.
A relatively high concentration of CaCl2 is required to crystallize 8RLOX, and AA is insoluble when at this concentration of CaCl2.
2. Trinary complexes of 8R-LOX, AA, and Xenon (an oxygen mimic)
should be achievable by preparing the binary complex as above and then
transferring the soaked crystals into a Xenon pressurization chamber.

4. SUMMARY AND CONCLUSIONS
The 8R-LOX from P. homomalla is an excellent model enzyme for
animal LOXs due to its robust overexpression and inherent protein stability.
Our lab’s undergraduate research students routinely execute the expression
and purification of 8R-LOX psWT. These aforementioned methods are
used as a training manual for new students, and these methods form the
foundation for developing expression and purification protocols for additional LOX enzymes. Our current understanding of animal LOXs has been
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greatly expanded with the multiple crystal structures of 8R-LOX, 8R-LOX
psWT, and 8R-LOX psWT with substrate.
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